Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Chiang, Cheryl Lai Lai ^a   Hagemann, Andrea R ^a   Leskowitz, Rachel ^a   Mick, Rosemarie ^a   Garrabrant, Thomas ^a   Czerniecki, Brian J ^a   Kandalaft, Lana E ^a   Powell, Daniel J ^a   Coukos, George ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P70; CYTOKINE; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; TISSUE EXTRACT;

ARTICLE; CELL LYSATE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOGENICITY; MYELOID DENDRITIC CELL; PHAGOCYTOSIS; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; BONE MARROW CELL; CELL DIFFERENTIATION; CROSS PRESENTATION; CYTOLOGY; DENDRITIC CELL; DONOR; DRUG EFFECT; FEMALE; HEALTH; IMMUNOLOGY; OVARY TUMOR; PATHOLOGY; PHENOTYPE; T LYMPHOCYTE; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CROSS-PRIMING; CYTOKINES; DENDRITIC CELLS; FEMALE; HEALTH; HUMANS; INTERFERON-GAMMA; LIPOPOLYSACCHARIDES; MYELOID CELLS; OVARIAN NEOPLASMS; PHAGOCYTOSIS; PHENOTYPE; T-LYMPHOCYTES; TISSUE DONORS; TISSUE EXTRACTS;

EID: 83355170576     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028732     Document Type: Article

References (35)

1. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332.
2. Hernando JJ, Park TW, Kübler K, Offergeld R, Schlebusch H, et al. (2002) Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 51: 45-52.
3. Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, et al. (2003) Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 13: 521-530.
4. Märten A, Renoth S, Heinicke T, Albers P, Pauli A, et al. (2003) Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14: 483-494.
5. Maier T, Tun-Kyi A, Tassis A, Jungius KP, Burg G, et al. (2003) Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102: 2338-2344.
6. Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, et al. (2003) A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother 26: 412-419.
7. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, et al. (2003) A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 52: 155-161.
8. Pandha HS, John RJ, Hutchinson J, James N, Whelan M, et al. (2004) Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 94: 412-418.
9. Thurner B, Röder C, Dieckmann D, Heuer M, Kruse M, et al. (1999) Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223: 1-15.
10. Berger TG, Strasser E, Smith R, Carste C, Schuler-Thurner B, et al. (2005) Efficient elutriation of monocytes within a closed system (Elutra(TM)) for clinical-scale generation of dendritic cells. J Immunol Methods 298: 61-72.
11. Berger TG, Feuerstein B, Strasser E, Hirsch U, Schreiner D, et al. (2002) Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories(TM). J Immunol Methods 268: 131-140.
12. Ardavin C, Amigorena S, Reis e Sousa C, (2004) Dendritic cells: immunobiology and cancer immunotherapy. Immunity 20: 17-23.
13. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, et al. (2000) Immunobiology of dendritic cells. Ann Rev Immunol 18: 767-811.
14. Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, et al. (2010) Harnessing human dendritic cell subsets for medicine. Immunol Rev 234: 199-212.
15. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, et al. (2007) Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67: 1842-1852.
16. Kvistborg P, Boegh M, Pedersen AW, Claesson MH, Zocca MB, (2009) Fast generation of dendritic cells. Cell Immunol 260: 56-62.
17. Dauer M, Obermaier B, Herten J, Haerle C, Pohl K, et al. (2003) Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 170: 4069-4076.
18. Dauer M, Lam V, Arnold H, Junkmann J, Kiefl R, et al. (2008) Combined use of toll-like receptor agonists and prostaglandin E2 in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production. J Immunol Methods 337: 97-105.
19. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, et al. (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421: 852-856.
20. Shedlock DJ, Shen H, (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300: 337-339.
21. Sun JC, Williams MA, Bevan MJ, (2004) CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 5: 927-933.
22. Neller MA, López JA, Schmidt CW, (2008) Antigens for cancer immunotherapy. Semin Immunol 20: 286-295.
23. Chiang CL, Benencia F, Coukos G, (2010) Whole tumor antigen vaccines. Semin Immunol 22: 132-143.
24. Rad AN, Pollara G, Sohaib SM, Chiang C, Chain BM, et al. (2003) The differential influence of allogeneic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation. Cancer Res 63: 5143-5150.
25. Tschoep K, Manning TC, Harlin H, George C, Johnson M, et al. (2003) Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines. J Leuko Biol 74: 69-80.
26. Loudovaris M, Hansen M, Suen Y, Lee SM, Casing P, et al. (2001) Differential effects of autologous serum on CD34+ or monocyte-derived dendritic cells. J Hematother Stem Cell Res 10: 569-578.
27. Gangur V, Simons FE, Hayglass KT, (1998) Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-γ over IL-4 responses. FASEB J 12: 705-713.
28. Wiechen K, Karaaslan S, Turzynski A, Dietel M, (1999) Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells. Br J Cancer 81: 790-795.
29. Yu D, Wolf JK, Scanlon M, Price JE, Hung M-C, (1993) Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53: 891-898.
30. Chiang CL, Ledermann J, Rad AN, Katz D, Chain B, (2006) Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells. Cancer Immunol Immunother 55: 1384-1395.
31. Liu A, Takahashi M, Narita M, Zheng Z, Kanazawa N, et al. (2002) Generation of functional and mature dendritic cells from cord blood and bone marrow CD34+ cells by two-step culture combined with calcium ionophore treatment. J Immunol Methods 261: 49-63.
32. Fay J, Palucka A, Paczesny S, Dhodapkar M, Johnston D, et al. (2006) Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide- pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother 55: 1209-1218.
33. Hayes M, Wang J, Norcross M, (1995) Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood 86: 646-650.
34. Trinchieri G, (1998) Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 16: 365-396.
35. Neville LF, Mathiak G, Bagasra O, (1997) The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): A novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 8: 207-219.